PLXP VS NVS Stock Comparison

Performance

PLXP
10/100

PLXP returned -96.94% in the last 12 months. Based on the other stocks in its sector with an average return of -31.58%, its performance is below average giving it a grade of 10 of 100.

NVS
100/100

NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.

Forecast

PLXP
75/100

1 analysts offer 12-month price forecasts for PLXP. Together, they have an average target of 0, the most optimistic forecast put PLXP at 0 within 12-months and the most pessimistic has PLXP at 0.

NVS

"Forecast" not found for NVS

Sentiment

PLXP
71/100

PLXP had a bullish sentiment score of 70.81% across Twitter and StockTwits over the last 12 months. It had an average of 9.26 posts, 0.97 comments, and 3.56 likes per day.

NVS

"Sentiment" not found for NVS

Technicals

PLXP
10/100

PLXP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

NVS
10/100

NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

PLXP
10/100

PLXP has missed earnings 9 times in the last 20 quarters.

NVS
39/100

NVS has missed earnings 5 times in the last 20 quarters.

Profit

PLXP
41/100

Out of the last 20 quarters, PLXP has had 8 profitable quarters and has increased their profits year over year on 6 of them.

NVS
73/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

PLXP
30/100

PLXP has had a lower than average amount of volatility over the last 12 months giving it a grade of 29 of 100.

NVS
44/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

PLXP

"Analyst Price Targets" not found for PLXP

NVS
67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.

All score calculations are broken down here to help you make more informed investing decisions

PLx Pharma Inc. Common Stock Summary

Nasdaq / PLXP

Healthcare

Drug Manufacturers—Specialty & Generic

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Novartis AG Summary

New York Stock Exchange / NVS

Healthcare

Drug Manufacturers - General

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Power up your portfolio